Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Report Presents Case Studies on Clinical Trial Failures

XTALKS VITALS NEWS

FDA

The report was meant to highlight the challenges associated with drug development, and the importance of the multistage drug approval process put in place by the FDA.

Share this!

January 27, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has released a report which presents case studies on 22 drugs in which Phase II clinical trial success did not translate to positive results in Phase III. The report was meant to highlight the challenges associated with drug development, and the importance of the multistage drug approval process put in place by the FDA.

“Roughly 9 in 10 drugs/biologics that are tested in humans are never submitted to FDA for approval,” said the authors of the FDA report. “Typically, a candidate drug is submitted to the FDA for marketing approval after phase III testing. In recent years, there has been growing interest in exploring alternatives to requiring phase III testing before product approval, such as relying on different types of data and unvalidated surrogate endpoints.”

While the agency fills an important role by ensuring that drug products on the market are safe and effective, some have criticized the agency for the length of time it takes for a new drug to be approved. Several candidates rumored to be on President Trump’s shortlist for FDA chief – including Jim O'Neill, Balaji Srinivasan and Joseph Gulfo – have expressed criticism of the FDA’s practices in the past.



Of the 22 case studies of drugs, vaccines and medical devices presented in the FDA’s report, 14 failed to meet efficacy endpoints in Phase III clinical trials. One drug – Pfizer’s cardiovascular disease drug, torcetrapib – failed due to an undesirable safety profile, while the remaining seven drugs had both unconfirmed safety and effectiveness in Phase III.

In the case of torcetrapib, Pfizer enrolled over 15,000 participants with a history of cardiovascular events and other risk factors into their Phase III clinical trial. Though the drug decreased cholesterol levels compared to the placebo, torcetrapib was also associated with a 25 percent increased risk of suffering a major adverse cardiovascular event.

After completion of Phase II trials for the drug, Pfizer executive Jeff Kindler said that torcetrapib could be “one of the most important developments in our generation.” This case study in particular highlights the importance of late-stage safety testing prior to approval.

“The 22 cases explored in this paper demonstrate that phase 2 results can inaccurately predict safety and/or effectiveness for medical products in a wide range of diseases and patient populations,” said the report. “As a result of the Phase III studies discussed in this paper, patients outside of clinical trials were not subjected to drugs that would not benefit them or to the risk of unnecessary serious toxicities, and did not suffer unnecessary financial expenditures.”


Keywords: FDA, Drug Approvals, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Study Finds Hospital-Acquired Anemia Linked with Poorer Patient Outcomes

May 19, 2017 - New research conducted at UT Southwestern Medical Center has found that one in three patients admitted to hospital develop anemia as a result.

Featured In: Life Science News


Scott Gottlieb Takes the Helm of the FDA

May 18, 2017 - One of the first things on his regulatory agenda is to address drug pricing – a hot topic in the US pharmaceutical industry today.

Featured In: Pharmaceutical News


Opioid Prescriptions for Minor Injuries Contribute to Growing Epidemic

May 18, 2017 - While many assume that patients prescribed large quantities of opioid drugs – such as oxycodone – for chronic pain are at the highest risk of abuse and dependence, new research suggests that small prescriptions for these narcotic painkillers could be just as dangerous.

Featured In: Drug Safety News


LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations


Respiratory Endpoints, Scientific Leadership and the Asia-Pacific Region


Imaging Diagnostics and Theranostics: Meeting Clinical Development Challenges


Enabling Patient-Centric Digital Transformation in Pharma and Biotech


Copyright © 2016-2017 Honeycomb Worldwide Inc.